Research Topics
Species | R HarropSummaryAffiliation: Medawar Centre Country: UK Publications
| Collaborators
|
Detail Information
Publications
Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinomaHoward L Kaufman
Tumor Immunology Laboratory, Division of Surgical Oncology, Columbia University, New York, NY, USA
J Transl Med 7:2. 2009..A modified vaccinia virus Ankara (MVA) encoding 5T4 was tested in combination with high-dose IL-2 to determine the safety, objective response rate and effect on humoral and cell-mediated immunity...- MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patientsRichard Harrop
Oxford BioMedica UK Ltd, The Medawar Centre, Oxford Science Park, Oxford, OX4 4GA, UK
Cancer Immunol Immunother 60:829-37. 2011.... - Characterization, cloning and immunogenicity of antigens released by transforming cercariae of Schistosoma mansoniR Harrop
Department of Biology, University of York
Parasitology 121:385-94. 2000..Such results will be discussed in the context of vaccine development... - Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patientsRichard Harrop
Oxford BioMedica UK Ltd, The Medawar Centre, Oxford, UK
J Immunother 33:999-1005. 2010..Although the studies were uncontrolled, there were encouraging signs of activity which is associated with the magnitude of 5T4-specific antibody responses... - Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responsesRichard Harrop
Oxford BioMedica UK Ltd, The Medawar Centre, Oxford Science Park, Oxford OX4 4GA, UK
Cancer Immunol Immunother 57:977-86. 2008..These data demonstrate that TroVax can be layered on top of chemotherapy regimens without any evidence of enhanced toxicity or reduced immunological or therapeutic efficacy... - Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responsesRichard Harrop
Oxford BioMedica UK Ltd, The Medawar Centre, Oxford, United Kingdom
Clin Cancer Res 13:4487-94. 2007..The primary objective was to assess the safety and immunogenicity of TroVax injected before, during, and after treatment with cycles of 5-fluorouracil, folinic acid, and oxaliplatin... - Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediatedRichard Harrop
Oxford BioMedica UK Ltd, The Medawar Centre, Oxford Science Park, OX4 4GA, Oxford, UK
Cancer Immunol Immunother 55:1081-90. 2006..Thus, we conclude that CD4+ T cells are essential for the induction of a protective immune response and that antibodies are the likely effector moiety in this xenogeneic murine tumor model... - Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trialRichard Harrop
Oxford BioMedica UK Ltd, The Medawar Centre, Oxford Science Park, Oxford, United Kingdom
Clin Cancer Res 12:3416-24. 2006..The primary objectives were to assess the safety and immunogenicity of ascending doses of TroVax and to determine the biodistribution of the vector... - Characterization, cloning and immunogenicity of antigens released by lung-stage larvae of Schistosoma mansoniR Harrop
Department of Biology, University of York
Parasitology 118:583-94. 1999..Analysis of the cellular immune responses of vaccinated mice showed 3 of the 4 expressed clones to be highly immunogenic, inducing the secretion of large quantities of the Th1-type cytokine interferon gamma... - Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4Irina Redchenko
Oxford BioMedica UK Ltd, Medawar Centre, Oxford Science Park, Oxford, UK
Immunology 118:50-7. 2006..These findings have potential application in cancer immunotherapy in terms of subunit vaccine design and the monitoring of immune responses induced in patients by 5T4-based therapies... - Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4William H Shingler
Oxford BioMedica UK Ltd, Medawar Centre, Oxford Science Park, Oxford, OX4 4GA, UK
Int Immunol 20:1057-66. 2008..Conclusion: iTopia represents a rapid and high-throughput technique to identify CTL epitopes... - Viral vectors for cancer immunotherapyRichard Harrop
Oxford BioMedica Ltd, Oxford Science Park, Oxford, OX4 4GA, United Kingdom
Front Biosci 11:804-17. 2006..Within the last 5-10 years, many such recombinant vectors have made the transition from pre-clinical research to clinical development and it is these, which are given most weight in this review... - Monitoring of human immunological responses to vaccinia virusRichard Harrop
Oxford BioMedica (UK) Ltd, Oxford, United Kingdom
Methods Mol Biol 269:243-66. 2004..The use of reliable immunological assays is vital in assessing the potential efficacy of new vaccines to protect against smallpox infection... - The schistosome egg: development and secretionsP D Ashton
Department of Biology, University of York
Parasitology 122:329-38. 2001..By immunocytochemistry, ESP localized predominantly to the envelope of the mature egg, suggesting that this layer rather than the miracidium is the source of egg secretions... - Recombinant viral vectors: cancer vaccinesRichard Harrop
Oxford BioMedica (U.K.) Ltd, Oxford Science Park, Oxford, OX4 4GA U.K
Adv Drug Deliv Rev 58:931-47. 2006.... - Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trialRobert J Amato
Department of Genitourinary Oncology Program, The Methodist Hospital Research Institute, 6560 Fannin, Houston, TX 77047, USA
J Immunother 31:577-85. 2008..The high frequency of 5T4-specific immune responses and relationship with enhanced time to progression is encouraging and warrants further investigation... - Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)Sylvia Janetzki
ZellNet Consulting, Inc, Fort Lee, NJ, USA
Cancer Immunol Immunother 57:303-15. 2008..These results provide initial harmonization guidelines to optimize Elispot assay performance to the immunotherapy community. Further optimization is in process with ongoing panels... - Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanomaJeremy P Braybrooke
Cancer Research UK Medical Oncology Unit, Churchill Hospital, Oxford OX3 7LJ, UK
Clin Cancer Res 11:1512-20. 2005..CONCLUSION: MetXia was safe and well tolerated. Gene transfer was detected at all dose levels, and the initial suggestion of an antitumor response indicates that MetXia-P450 should undergo further clinical assessment...